Gufic BioSciences Ltd Fundamentals
Gufic BioSciences Ltd Financials
Resistance and Support
₹343.15
PIVOT
 Resistance | |
|---|---|
| First Resistance | ₹348.050 |
| Second Resistance | ₹352.900 |
| Third Resistance | ₹357.800 |
 Support | |
|---|---|
| First Support | ₹338.300 |
| Second Support | ₹333.400 |
| Third Support | ₹328.550 |
Delivery and Volume
About Gufic BioSciences Ltd
Gufic Biosciences (GBL) was incorporated in Jul'84. The Company is a result of a reverse merger of itself with Central Finance. The promoters of GBL took over Central Finance at Rs 40-42 per share and then got GBL listed on BSE. Presently, the Company is engaged in the manufacturing and marketing of active pharmaceutical ingredients, generic pharmaceuticals and related services. The Choksi and Gandhi family, the promoters of GBL, have a long-standing presence in the pharma industry. In 1960, the family set up a joint venture company called Lyka Labs. In 1976, they decided to part ways and the Choksi family took over the manufacturing facility and the Gufic group of companies was born. Initially known as Gujarat Fine Chemicals, the first foray of the Gufic group was in the manufacture of various bulk drugs. The company later entered the formulation market. Currently, the overall profile of GBL comprises ethical products, herbal products, consumer products and bulk drugs that are sold in the domestic and the international markets. Over the past several years, the company have a known reputation of creating brands that have vaulted to leadership positions in the category in which they have been marketed. To mention a few names: Shapers (sanitary napkins), Onergy, and Stretch nil. In the year 2000, the company issued Bonus Equity Shares in proportion of five Equity shares for every two Equity shares held. Gufic has divested brands in the ethical pharma business in a seller's market. The company plan to invest further in R&D activities and aggressively enter the herbal product and consumer product segments, where it foresee a huge potential. While benefiting from the rich, traditional knowledge base in India, it would like to operate from an area of strength in the herbal products segment. In 2020-21, Gufic Lifesciences Private Limited amalgamated with the Company through the Scheme of Amalgamation which became effective from May 21, 2021. GUFIC UK LIMITED (GUL), a wholly owned subsidiary of the Company, was incorporated in United Kingdom on March 15, 2022. Similarly, in 2023, Gufic Ireland Limited (GIL) was incorporated on March 02, 2023.
Managing Director
1984
Founded
Jayesh P Choksi
NSE Symbol
GUFICBIO
Gufic BioSciences Ltd Management
| Name | Designation |
|---|---|
| Jayesh P Choksi | Chairman & Managing Director |
| Pranav J Choksi | Whole Time Director & CEO |
| Pankaj Gandhi | Whole-time Director |
| Shreyas Patel | Non-Exec. & Independent Dir. |
| Ami Naresh Shah | Company Sec. & Compli. Officer |
| Gopal Daptari | Non-Exec. & Independent Dir. |
| Shrirang V Vadiya | Non-Exec. & Independent Dir. |
| Balram Singh | Non-Exec & Non-Independent Dir |
| Rabi Narayan Sahoo | Non-Exec. & Independent Dir. |
| Anusanjiv Aurora | Non-Exec. & Independent Dir. |
| Dilip Ghosh | Whole-time Director |
Events
Dividend Announcement for Gufic BioSciences Ltd - May 29, 2023
On May 29, 2023, shareholders are set to receive a dividend payout, with each share entitling its holder to a dividend of 10.0%. This dividend percentage reflec...
Read MoreGufic BioSciences Ltd News
Similar Stocks
| Company | Market Cap | Market Price | P/E Ratio |
|---|---|---|---|
| Sun Pharmaceuticals Industries Ltd | ₹ 367554.12 Cr | ₹ 1,531.90 (0.03 %) | 89.16 |
| Cipla Ltd | ₹ 113362.29 Cr | ₹ 1,404.05 (0.36 %) | 30.52 |
| Zydus Lifesciences Ltd | ₹ 111083.2 Cr | ₹ 1,103.95 (5.00 %) | 41.35 |
| Divis Laboratories Ltd | ₹ 104302.61 Cr | ₹ 3,929.00 (0.47 %) | 76.42 |
| Dr Reddys Laboratories Ltd | ₹ 96948.1 Cr | ₹ 5,811.60 (0.21 %) | 22.34 |